Homa Yeganegi
Hoofd Techniek/Wetenschap/O&O bij AGENUS INC.
Actieve functies van Homa Yeganegi
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
AGENUS INC. | Hoofd Techniek/Wetenschap/O&O | 20-07-2023 | - |
Loopbaan van Homa Yeganegi
Eerdere bekende functies van Homa Yeganegi
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
TURG POIN | Corporate Officer/Principal | 06-01-2020 | - |
CLOVIS ONCOLOGY, INC. | Corporate Officer/Principal | - | - |
HALOZYME THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-03-2016 | - |
Corporate Officer/Principal | - | - |
Opleiding van Homa Yeganegi
University of Tehran | Undergraduate Degree |
The University of Western Australia | Graduate Degree |
Statistieken
Internationaal
Verenigde Staten | 5 |
Iran | 2 |
Australië | 2 |
Operationeel
Corporate Officer/Principal | 3 |
Chief Tech/Sci/R&D Officer | 2 |
Undergraduate Degree | 1 |
Sectoraal
Health Technology | 5 |
Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
HALOZYME THERAPEUTICS, INC. | Health Technology |
AGENUS INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Turning Point Therapeutics, Inc.
Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Clovis Oncology, Inc.
Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
- Beurs
- Insiders
- Homa Yeganegi
- Ervaring